VericelFRA:ATQP -1.07%75 FCF Yield % is 2.01 as of Jun. 29, 2026. GuruFocus rates FRA:ATQP with a GF Score™ of 75/100 and a GF Value™ of €43.45 (Modestly Undervalued). The stock has 7 warning signs investors should review. Among 1,415 Biotechnology companies, Vericel ranks better than 88.34% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Vericel's Trailing 12-Month Free Cash Flow is €40.7 Mil, and Market Cap is €2,078.0 Mil. Therefore, Vericel's FCF Yield % for today is 2.01%.
The historical rank and industry rank for Vericel's FCF Yield % or its related term are showing as below:
FRA:ATQP'
s FCF Yield % Range Over the Past 10 Years
Min: -33.67 Med: -0.13 Max: 2.83
Current: 2.01
During the past 13 years, the highest FCF Yield % of Vericel was 2.83%. The lowest was -33.67%. And the median was -0.13%.
FRA:ATQP's FCF Yield % is ranked better than 88.34% of 1415
companies
in the Biotechnology industry
Industry Median: -9.62
vs FRA:ATQP: 2.01
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Vericel FCF Yield % Related Terms
Vericel FCF Yield % Historical Data
* Premium members only.
The historical data trend for Vericel's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:ATQP vs NRIX, MLYS, PHVS: FCF Yield % Comparison
For the Biotechnology subindustry, Vericel's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vericel FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vericel's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Vericel's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vericel (FRA:ATQP) has a FCF Yield % of 2.01 as of Jun. 29, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vericel and its competitors. According to the industry distribution chart, Vericel ranks #165 out of 1415 companies in the Biotechnology industry, placing it in the top 11.7%.
Is Vericel's FCF Yield % too high?
Vericel's current FCF Yield % is 2.01. Based on the distribution chart, Vericel ranks #165 out of 1415 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Vericel has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vericel's FCF Yield % compare to NRIX and MLYS?
According to the Biotechnology industry distribution chart, Vericel ranks #165 out of 1415 companies for FCF Yield %. This places Vericel in the top 12% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Vericel and its competitors. Vericel's current FCF Yield % is 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vericel stock overvalued right now?
Based on GuruFocus' analysis, Vericel (FRA:ATQP) is currently considered Modestly Undervalued. The stock's GF Value™ is €43.45, compared to a current price of €37.00 — trading 14.8% below its estimated fair value. The current FCF Yield % is 2.01. Vericel's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Vericel (FRA:ATQP), the current FCF Yield % is 2.01 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vericel (FRA:ATQP) Overvalued in 2026?
Based on GuruFocus' analysis, Vericel stock appears to be undervalued.
The current stock price of €37.00 is trading 14.8% below its estimated GF Value™ of €43.45.
GuruFocus considers Vericel to be Modestly Undervalued.
Key valuation signals for FRA:ATQP:
FCF Yield %: 2.01
GF Value™: €43.45 vs. price of €37.00 (14.8% below fair value)
No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
75GF Score
Get the complete analysis for FRA:ATQP
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ATQP has been successfully added to your 
